Access

Commentary

Nature Nanotechnology 3, 242–244 (1 May 2008) | doi:10.1038/nnano.2008.114

Seven challenges for nanomedicine

Wendy R. Sanhai , Jason H. Sakamoto , Richard Canady & Mauro Ferrari

The marriage of nanotechnology and medicine has yielded an offspring that is set to bring momentous advances in the fight against a range of diseases. Nanomedicine is actually a child well past its infancy, with two families of therapeutic nanocarriers — liposomes and albumin nanoparticles — firmly in clinical practice worldwide, a dozen or so therapeutic agents in clinical trials, and still more in the preclinical phases of development.